Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Feb 1, 2017
Clinical News

Emixustat: Ph IIa started

BioCentury | Jun 20, 2016
Company News

Otsuka Pharmaceutical, Acucela deal

BioCentury | May 30, 2016
Clinical News

Emixustat: Phase IIb/III data

BioCentury | May 27, 2016
Clinical News

Acucela's emixustat fails in AMD study

BioCentury | May 16, 2016
Clinical News

Emixustat: Phase II started

BioCentury | Jun 8, 2015
Clinical News

Emixustat: Phase IIa data

BioCentury | Jun 5, 2015
Clinical News

Acucela gains on Phase II emixustat data

BioCentury | Mar 10, 2014
Clinical News

Emixustat: Completed Phase IIb/III enrollment

BioCentury | Feb 17, 2014
Finance

Visually exciting in Japan

Acucela trades up after massive IPO in Japan despite headwinds
Items per page:
1 - 10 of 29